EUVIMEDEUVIMED entdecken
Crossref

Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease

Johnson Thomas

Clinical Thyroidology® · 01.11.2026 · 38 (11) · 374-376

DOI: 10.1177/23299711261506080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Thyroidology®, online erschienen am 16.11.2026. Verfasst von Johnson Thomas. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Thomas, J. (2026). Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease. Clinical Thyroidology®, 38(11), 374-376. https://doi.org/10.1177/23299711261506080

Vancouver

Thomas J. Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease. Clinical Thyroidology®. 2026;38(11):374-376. doi:10.1177/23299711261506080

BibTeX
@article{Thomas2026,
  author = {Thomas, Johnson},
  title = {Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease},
  journal = {Clinical Thyroidology®},
  year = {2026},
  volume = {38},
  number = {11},
  pages = {374--376},
  doi = {10.1177/23299711261506080}
}
Kostenlos starten →